What is ANRO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.87B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ANRO?

P/E (TTM) is n/a and 52-week range is $10.20 to $37.48 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ANRO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ANRO?

The company profile lists net income (TTM) near -$96M, EPS (TTM) near -$2.44 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Alto Neuroscience Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Mountain View, California, US, 39.2M shares outstanding, ISIN US02157Q1094 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Alto Neuroscience Inc (ANRO) Stock Analysis & Quote

Alto Neuroscience Inc

$ANRO

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. The company is headquartered in Mountain View, California and currently employs 68 full-time employees. The company went IPO on 2024-02-02. The firm's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.

Employees

Website

www.altoneuroscience.com/

IPO

2024-02-02

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NEW YORK STOCK EXCHANGE, INC.

ISIN

US02157Q1094

Headquarters

Mountain View, California, US

Shares outstanding

39.2M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

82.19%

Browse other companiesFree AI scores and summaries for more stocks